Loading
NYSEHealthcareDrug Manufacturers - General
Latest quote
$38.26
+$0.73 · +1.95%
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Previous close
$38.26
+$0.73 · +1.95%
Pre-market
$37.78
−$0.48 · -1.25%
Oct 8, 9:03 AM ET
Regular session · ET · Market data may be delayed.
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Day range
Current $38.26
52-week range
Current $38.26
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
99
Deep Value
Sentiment
52
Mixed
Risk
34
Moderate Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Day range
Current $38.26
52-week range
Current $38.26
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (DKK) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 309.06B DKK | 290.4B DKK | 232.26B DKK | 176.95B DKK | 140.8B DKK |
| Cost of goods sold | 58.79B DKK | 44.52B DKK | 35.77B DKK | 28.45B DKK | 23.66B DKK |
| Gross profit | 250.28B DKK | 245.88B DKK | 196.5B DKK | 148.51B DKK | 117.14B DKK |
| Research and development | 52.04B DKK | 48.06B DKK | 32.44B DKK | 24.05B DKK | 17.77B DKK |
| Selling, general, and administrative | 70.28B DKK | 67.38B DKK | 61.6B DKK | 50.68B DKK | 41.06B DKK |
| Operating expenses | 122.62B DKK | 117.54B DKK | 93.92B DKK | 73.7B DKK | 58.5B DKK |
| Interest income | 1.27B DKK | 1.84B DKK | 1.07B DKK | 239M DKK | 231M DKK |
| Interest expense | 4.21B DKK | 1.64B DKK | 542M DKK | 378M DKK | 289M DKK |
| Depreciation and amortization | 21.98B DKK | 19.11B DKK | 9.41B DKK | 7.36B DKK | 6.03B DKK |
| Operating income | 127.66B DKK | 128.34B DKK | 102.57B DKK | 74.81B DKK | 58.64B DKK |
| Net income | 102.43B DKK | 100.99B DKK | 83.68B DKK | 55.53B DKK | 47.76B DKK |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$44.67
16.75% upsideFunds reporting this stock among their holdings, ordered by reported position size.
VanEck Pharmaceutical ETFPPH56.93M5.61%1.03B USD0.36%$109.49+1.22%
Avantis International Equity ETFAVDE51.27M0.27%19.28B USD0.23%$89.48-1.21%
First Trust WCM International Equity ETFWCMI30.54M1.44%2.12B USD0.85%$18.99-1.58%
Invesco International Dividend Achievers ETFPID16.63M1.95%854.02M USD0.53%$21.49-0.42%
Hartford Multifactor Developed Markets (ex-US) ETFRODM11.01M0.68%1.62B USD0.29%$40.55-0.83%
Avantis International Large Cap Value ETFAVIV10.9M0.53%2.05B USD0.25%$78.70-1.08%
ActivePassive International Equity ETFAPIE8.34M0.73%1.18B USD0.45%$38.58-1.25%
Roundhill Investments - GLP-1 & Weight Loss ETFOZEM6.46M11.45%56.4M USD0.59%$30.0942-0.04%VanEck Pharmaceutical ETFPPHAvantis International Equity ETFAVDEFirst Trust WCM International Equity ETFWCMIInvesco International Dividend Achievers ETFPIDHartford Multifactor Developed Markets (ex-US) ETFRODMAvantis International Large Cap Value ETFAVIVActivePassive International Equity ETFAPIERoundhill Investments - GLP-1 & Weight Loss ETFOZEMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
